The Workbench · Craft
A Warning Letter closes on proof, not a promise
This blog has already covered the narrow, statutory channel a device firm can use to ask FDA whether a proposed fix to a Form 483 observation is adequate, and the Official Action Indicated classification that can lead to a Warning Letter in the first place. Neither post reaches what actually ends a Warning Letter once one is issued. A firm's written response is the expected next move, and FDA's own Regulatory Procedures Manual describes a usual timeframe for sending one — but a response is not a close, and a compliance file that marks a Warning Letter resolved the day the firm's letter goes out has confused the two.
An advisory action, not a statutory one
A Warning Letter isn't created by a section of the FD&C Act the way a Form 483 traces to section 704(b) or a clinical hold traces to section 520(g)(8). It's an advisory action FDA describes in its own Regulatory Procedures Manual, issued after a district or center reviews the inspectional record — often including the firm's own 483 response — and decides the violations found warrant a formal notice before FDA considers stronger measures. That administrative origin matters for a compliance file: there's no statute setting a firm's response deadline, only FDA's own stated practice, and the specific window named in the letter received governs over any general assumption about how long a firm has.
The response window is FDA's stated practice, not a guarantee
The Regulatory Procedures Manual describes a firm as expected to investigate, correct what it can, and send a written response within a period the letter itself states — commonly around fifteen working days from receipt, the same figure this blog has already noted governs the general Form 483 response FDA expects. That figure isn't a right the firm can rely on being extended, and it isn't a ceiling FDA is bound to either; the window that actually applies is the one printed in the letter a firm received, not a fixed number a tracker can hard-code once and reuse for every Warning Letter that follows.
A response is not what closes the file
Sending a written response, even a thorough one, doesn't end a Warning Letter on its own. FDA evaluates the corrective actions the firm proposes and, before treating the matter as resolved, verifies that those actions were actually carried out and that the violations were actually corrected — commonly through a follow-up inspection, not through a re-read of the firm's own written account. A corrective action plan that reads as adequate on paper still has to hold up against that verification step before FDA will call the matter closed.
The close-out letter is the only document that says so
Only a close-out letter actually ends a Warning Letter, and FDA issues one specifically after it has evaluated the firm's response, verified the violations were corrected, and found no additional violations during that verification. A close-out letter isn't issued on the strength of the firm's representations alone, and it isn't issued at all where the Warning Letter cited a violation that, by its nature, can't be corrected after the fact. A tracker that logs a Warning Letter as closed once the firm's response is filed, rather than once a close-out letter actually arrives, is recording the wrong event as the ending.
Closed still isn't cleared
A close-out letter doesn't function as a clean bill of health going forward. It reflects FDA's judgment on the specific violations that letter named, not a commitment to forgo future inspection or enforcement, and it doesn't retroactively change how the underlying inspection was classified. Where a Warning Letter goes unanswered or the response proves inadequate, the same escalation path that can lead to an import alert stays open — a close-out letter forecloses that path for the cited violations, and nothing more.
Where this meets the file
A Warning Letter tracker needs three separate dated fields, not one status column: the firm's response, on the deadline that specific letter actually states; FDA's verification activity, typically a follow-up inspection rather than a paper review; and the close-out letter itself, the only event that actually ends the matter. A Warning Letter response and close-out tracker built around that three-part structure is previewed in the launch catalog. If your program tracks a Warning Letter's lifecycle differently, the shelf takes that correction directly.
The Regulatory Toolkit launches soon — a free shelf of source-mapped templates, checklists and browser-only tools for regulatory teams. Get one email when it opens, or contribute a template.